IRD

+ Watchlist + Portfolio

Opus Genetics, Inc.

Regulated industry Physical products Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $4.51
52-Week Range: $1.70 – $7.07
Market Cap: $381.04M
P/E (TTM): —
EPS (TTM): -1.27
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: —
PEG Ratio: —
Return on Equity: -4796.52%
Return on Assets: -48.06%
Gross Margin: -291.85%
Operating Margin: -2182.78%
Profit Margin: 0.00%
Current Ratio: 12.19
Debt/Equity: —
Total Debt: $36.20M
Free Cash Flow: $-38.56M
Revenue Growth: -73.80%
Earnings Growth: —
Enterprise Value: $328.43M

IRD Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$39.85M	$19.05M	$10.99M	$14.20M
Research & Development	$14.36M	$17.65M	$26.85M	$30.81M
Selling, General & Admin	$7.27M	$11.96M	$18.21M	$21.98M
Operating Expenses	$21.62M	$29.61M	$45.07M	$52.80M
Operating Income	$18.23M	-$10.56M	-$34.07M	-$38.60M
EBITDA	$18.22M	-$8.64M	-$57.52M	-$48.07M
Pretax Income	$18.20M	-$9.97M	-$57.53M	-$49.59M
Income Tax	$315.00K	$12.00K	$0.00	$0.00
Net Income	$17.89M	-$9.99M	-$57.53M	-$49.59M
Diluted EPS	0.87	-0.46	-2.15	-0.80
Diluted Shares	20.60M	21.59M	26.72M	62.22M

IRD Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$42.63M	$50.50M	$30.32M	$45.09M
Receivables	$4.85M	$2.33M	$5.77M	$3.17M
Current Assets	$48.99M	$53.95M	$36.61M	$50.04M
Total Assets	$48.99M	$53.95M	$36.86M	$50.24M
Current Liabilities	$2.75M	$4.04M	$11.29M	$7.78M
Long-Term Debt	—	—	—	$1.13M
Total Debt	—	—	—	$1.13M
Total Liabilities	$2.75M	$4.04M	$30.14M	$34.90M
Retained Earnings	-$71.48M	-$81.47M	-$139.00M	-$188.59M
Shareholders' Equity	$46.24M	$49.91M	$6.72M	$15.35M
Working Capital	$46.23M	$49.91M	$25.32M	$42.26M

IRD Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	$14.31M	-$1.11M	-$25.58M	-$35.25M
Free Cash Flow	$14.31M	-$1.11M	-$25.58M	-$35.25M
Depreciation & Amortisation	$4.00K	$6.00K	$10.00K	$53.00K
Stock-Based Compensation	$1.81M	$3.51M	$3.36M	$3.40M
Investing Cash Flow	$0.00	$0.00	$1.21M	$0.00
Financing Cash Flow	$3.79M	$8.98M	$4.19M	$50.02M
Share Repurchases	—	$0.00	-$79.00K	-$152.00K
Net Change in Cash	$18.10M	$7.87M	-$20.18M	$14.77M

IRD Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$4.37M	$2.88M	$3.08M	$3.87M	$2.16M	$755.00K
Research & Development	$7.95M	$6.02M	$6.41M	$10.43M	$10.58M	$11.21M
Selling, General & Admin	$6.35M	$5.77M	$4.98M	$4.89M	$5.94M	$6.03M
Operating Expenses	$14.30M	$11.79M	$11.39M	$15.32M	$16.52M	$17.23M
Operating Income	-$9.93M	-$8.91M	-$8.31M	-$11.45M	-$14.36M	-$16.48M
EBITDA	-$6.81M	-$8.89M	-$17.37M	-$15.11M	-$64.87M	-$7.55M
Pretax Income	-$8.19M	-$7.42M	-$17.45M	-$16.52M	-$65.53M	-$8.10M
Income Tax	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Net Income	-$8.19M	-$7.42M	-$17.45M	-$16.52M	-$65.53M	-$8.10M
Diluted EPS	-0.24	-0.12	-0.25	—	-0.75	-0.14
Diluted Shares	33.88M	63.38M	70.64M	—	86.89M	111.38M

IRD Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$41.79M	$32.43M	$30.82M	$45.09M	$59.96M	$88.81M
Receivables	$4.75M	$4.58M	$4.28M	$3.17M	$2.71M	$1.46M
Current Assets	$47.93M	$38.44M	$35.91M	$50.04M	$66.60M	$92.70M
Total Assets	$48.17M	$38.66M	$36.12M	$50.24M	$66.79M	$92.97M
Current Liabilities	$24.25M	$20.19M	$29.09M	$7.78M	$9.34M	$7.61M
Long-Term Debt	—	$1.00M	$1.07M	$1.13M	$1.20M	$36.20M
Total Debt	—	$1.00M	$1.07M	$1.13M	$1.20M	$36.20M
Total Liabilities	$43.09M	$21.19M	$30.16M	$34.90M	$112.62M	$105.95M
Retained Earnings	-$147.19M	-$154.61M	-$172.07M	-$188.59M	-$254.12M	-$262.22M
Shareholders' Equity	$5.07M	$17.47M	$5.97M	$15.35M	-$45.84M	-$12.99M
Working Capital	$23.68M	$18.25M	$6.82M	$42.26M	$57.26M	$85.09M

IRD Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$8.99M	-$10.27M	-$6.16M	-$9.83M	-$12.73M	-$11.95M
Free Cash Flow	-$8.99M	-$10.27M	-$6.16M	-$9.83M	-$12.73M	-$11.95M
Depreciation & Amortisation	$13.00K	$14.00K	$13.00K	$13.00K	$13.00K	$14.00K
Stock-Based Compensation	$913.00K	$896.00K	$816.00K	$774.00K	$1.46M	$1.41M
Investing Cash Flow	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Financing Cash Flow	$20.46M	$906.00K	$4.54M	$24.11M	$27.59M	$40.90M
Share Repurchases	-$36.00K	$0.00	$0.00	-$116.00K	-$33.00K	$0.00
Net Change in Cash	$11.47M	-$9.36M	-$1.61M	$14.28M	$14.87M	$28.95M

Market Snapshot

About

Opus Genetics is a biotechnology company focused on developing genetic medicines for inherited retinal diseases and other genetic disorders. The company utilizes its proprietary gene therapy platforms to create treatments targeting the underlying genetic causes of vision loss and blindness. Opus Genetics is advancing a pipeline of product candidates designed to restore or preserve vision in patients with rare inherited eye diseases. The company combines cutting-edge genetic engineering with clinical development expertise to bring transformative therapies to patients with limited treatment options.